Patents by Inventor James Francis HULVAT

James Francis HULVAT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HBV
    Publication number: 20220241208
    Abstract: The present disclosure provides, in part, pharmaceutical compositions that comprise a spray dried dispersion which contains the disclosed compound, and optionally, pharmaceutical excipients. The pharmaceutical compositions of the disclosure may be used in the treatment of Hepatitis B (HBV).
    Type: Application
    Filed: May 22, 2020
    Publication date: August 4, 2022
    Inventors: Lee D. ARNOLD, George Koan WONG, Kirk HENNE, James Francis HULVAT, Sanjay KONAGURTHU, Ian Scott MCINTOSH, Matthew David WESSEL, Thomas REYNOLDS, Richard J. COLONNO, Uri A. LOPATIN
  • AMORPHOUS SPARSENTAN COMPOSITIONS
    Publication number: 20220048900
    Abstract: An amorphous form of a compound having structure (I), or a pharmaceutically acceptable salt thereof, is provided. Such compounds may be used for the treatment of kidney diseases or disorders.
    Type: Application
    Filed: December 20, 2019
    Publication date: February 17, 2022
    Inventors: Dainius Macikenas, Kale Ruby, James Francis Hulvat, Xiangming Wu
  • NOVEL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR
    Publication number: 20190282578
    Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: October 19, 2018
    Publication date: September 19, 2019
    Inventors: Harisha Atluri, Ching Wah Chong, Robert Kuehl, Cassandra Shu, Pearl Shwe-Cho Tay, James Francis Hulvat, Alexander Jacob McVey, Ryan Mitchell Minikis
  • Formulations of a Bruton's tyrosine kinase inhibitor
    Patent number: 10105368
    Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: October 23, 2018
    Assignee: Pharmacyclics LLC
    Inventors: Harisha Atluri, Ching Wah Chong, Robert Kuehl, Cassandra Shu, Pearl Shwe-Cho Tay, James Francis Hulvat, Alexander Jacob McVey, Ryan Mitchell Minikis
  • Novel Formulations of a Bruton's Tyrosine Kinase Inhibitor
    Publication number: 20180028537
    Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: March 17, 2017
    Publication date: February 1, 2018
    Inventors: Harisha Atluri, Ching Wah Chong, Robert Kuehl, Cassandra Shu, Pearl Shwe-Cho Tay, James Francis Hulvat, Alexander Jacob McVey, Ryan Mitchell Minikis
  • Formulations of a bruton's tyrosine kinase inhibitor
    Patent number: 9545407
    Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: January 17, 2017
    Assignee: Pharmacyclics LLC
    Inventors: Cassandra Shu, Harisha Atluri, Robert Kuehl, Pearl Shwe-Cho Tay, Ryan Mitchell Minikis, James Francis Hulvat, Alexander Jacob McVey, Ching Wah Chong
  • NOVEL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR
    Publication number: 20160038496
    Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: August 7, 2015
    Publication date: February 11, 2016
    Inventors: Cassandra SHU, Harisha ATLURI, Robert KUEHL, Pearl Shwe-Cho TAY, Ryan Mitchell MINIKIS, James Francis HULVAT, Alexander Jacob MCVEY